Searched for
BIOGENS ADUHELM
Pharma CMOs may feel heat as USFDA approves fewer new drugs, GlobalData report saysInflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, stated GlobalData in its latest ...- Roche's Alzheimer's drug fails to meet goal in long awaited trialRoche's Alzheimer's drug candidate could not be shown to markedly slow dementia progression in two drug trials, leaving rivals Biogen and E...
- Biogen appoints ex-Sinofi boss Christopher Viehbacher as its next CEO. Here are the detailsAfter a month gap in choosing the new CEO after Michel Vounatsos, Biogen has finally named Christopher Viehbacher as its new CEO.
- Lecanemab: All about the Alzheimer's drug that shows promiseClinical trials on 1800 patients with early-stage Alzheimer's has showed that Lecanemab slows the advance of the disease.
- Biogen halves price of Alzheimer's drug to $28,200Biogen's $56,000 per year treatment price for an average weight person was seen as a significant cost burden on Medicare, which covers more...
- Wall Street rises on J&J, big tech boostThe S&P 500 and Dow indexes tracked weekly declines of about 1 per cent, their first since the turn of October, as hot US inflation reading...
- Wall Street ekes out gains to close languid weekThe Nasdaq gained the most among the three major indexes, while the bellwether S&P 500 squeaked its way to a second straight record closing...
Load More